ABI
IPXL

Adamant Biomedical Investments’s Impax Laboratories, Inc. IPXL Stock Holding History

Adamant Biomedical Investments’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$634K Hold
20,000
– – 0.15% 88
2014
Q3 		$474K Buy
+20,000
New +$512K 0.12% 88

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Adamant Biomedical Investments's IPXL Position: Q4 2014 in Review

Adamant Biomedical Investments held its Impax Laboratories, Inc. (IPXL) position steady in Q4 2014 at 20,000 shares worth $634K. The position accounts for 0.15% of the portfolio, ranked #88.

Adamant Biomedical Investments first reported a position in IPXL in Q3 2014 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold IPXL as of Q4 2014.

  • Adamant Biomedical Investments held 20,000 shares of Impax Laboratories, Inc. worth $634K as of Q4 2014.
  • Adamant Biomedical Investments left its Impax Laboratories, Inc. share count unchanged in Q4 2014.
  • Impax Laboratories, Inc. made up 0.15% of Adamant Biomedical Investments's portfolio in Q4 2014, its #88 holding.
  • Adamant Biomedical Investments first reported a position in Impax Laboratories, Inc. in Q3 2014 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.